Fractalkine and inflammatory diseases

Japanese Journal of Clinical Immunology

Volumn 28, Issue 3, 2005, Pages 131-139

  Imai, Toshio ^a   Nishimura, Miyuki ^a   Nanki, Toshihiro ^b   Umehara, Hisanori ^c  

^a KAN Research Institute ^*  (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

cell migration; chronic inflammatory disease; cytotoxic lymphocytes; fractalkine CX3CL1; mucosal immunity

Indexed keywords

CHEMOKINE (C X3 C MOTIF) LIGAND 1; CHEMOKINE (C-X3-C MOTIF) LIGAND 1; CX3C CHEMOKINE; MEMBRANE PROTEIN;

ANIMAL; HUMAN; IMMUNOLOGY; INFLAMMATION; PHYSIOLOGY; REVIEW;

ANIMALS; CHEMOKINES, CX3C; HUMANS; INFLAMMATION; MEMBRANE PROTEINS;

EID: 23444460418     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.28.131     Document Type: Article

References (53)

1. Butcher E., Williams M., Youngman K., et al. : Lymphocyte trafficking and regional immunity. Adv Immunol. 72 : 209–253, 1999.
2. Butcher E. : Leukocyte-endothelial cell recognition : Three (or more) steps to specificity and diversity. Cell 67 : 1033–1036, 1991.
3. Umehara H., Bloom E., Okazaki T., et al. : Fractalkine and vascular injury. Trends Immunol 22 : 602–607, 2001.
4. Bazan Jf., Bacon Kb., Hardiman G., et al. : A new class of membrane-bound chemokine with a CX3C motif. Nature 385 : 640–644, 1997.
5. Yoshie O., Imai T., and Nomiyama H. : Chemokines in immunity. Adv Immunol 78 : 57–110, 2001.
6. Fong Am., Erickson Hp., Zachariah Jp., et al. : Ultrastructure and function of the fractalkine mucin domain in CX(3)C chemokine domain presentation. J Biol Chem 275 : 3781–3786, 2000.
7. Imaizumi T., Yoshida H., and Satoh K. : Regulation of CX3CL1/fractalkine expression in endothelial cells. J Atheroscler Thromb 11 : 15–21, 2004.
8. Fraticelli P., Sironi M., Bianchi G., et al. : Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 107 : 1173–1181, 2001.
9. Shiraishi K., Fukuda S., Mori T., et al. : Identification of fractalkine, a CX3C-type chemokine, as a direct target of p53. Cancer Res 60 : 3722–3726, 2000.
10. Tsou Cl., Haskell Ca., and Charo If. : Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J Biol Chem 276 : 44622–44626, 2001.
11. Garton Kj., Gough Pj., Blobel Cp., et al. : Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276 : 37993–38001, 2001.
12. Imai T., Hieshima K., Haskell C., et al. : Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91 : 521–530, 1997.
13. Faure S., Meyer L., Costagliola D., et al. : Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 287 : 2274–2277, 2000.
14. Moatti D., Faure S., Fumeron F., et al. : Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 97 : 1925–1928, 2001.
15. Goda S., Imai T., Yoshie O., et al. : CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J Immunol 164 : 4313–4320, 2000.
16. Hundhausen C., Misztela D., Berkhout Ta., et al. : The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102 : 1186–1195, 2003.
17. Fong Am., Robinson La., Steeber Da., et al. : Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 188 : 1413–1419, 1998.
18. Fong Am., Alam Sm., Imai T., et al. : CX3CR1 tyrosine sulfation enhances fractalkine-induced cell adhesion. J Biol Chem 277 : 19418–19423, 2002.
19. Nishimura M., Umehara H., Nakayama T., et al. : Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 168 : 6173–6180, 2002.
20. Yoneda O., Imai T., Goda S., et al. : Fractalkinemediated endothelial cell injury by NK cells. J Immunol 164 : 4055–4062, 2000.
21. Yoneda O., Imai T., Nishimura M., et al. : Membrane-bound form of fractalkine induces IFN-gamma production by NK cells. Eur J Immunol 33 : 53–58, 2003.
22. Geissmann F., Jung S., and Littman Dr. : Blood Monocytes Consist of Two Principal Subsets with Distinct Migratory Properties. Immunity 19 : 71–82, 2003.
23. Ancuta P., Rao R., Moses A., et al. : Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 197 : 1701–1707, 2003.
24. Sunderkotter C., Nikolic T., Dillon Mj., et al. : Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 172 : 4410–4417, 2004.
25. Jung S., Aliberti J., Graemmel P., et al. : Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 20 : 4106–4114, 2000.
26. Niess Jh., Brand S., Gu X., et al. : CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 307 : 254–258, 2005.
27. Rescigno M., Urbano M., Valzasina B., et al. : Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2 : 361–367, 2001.
28. Schafer A., Schulz C., Eigenthaler M., et al. : Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion. Blood 103 : 407–412, 2004.
29. Meucci O., Fatatis A., Simen Aa., et al. : Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci U S A 95 : 14500–14505, 1998.
30. Volin Mv., Woods Jm., Amin Ma., et al. : Fractalkine : A novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol 159 : 1521–1530, 2001.
31. Umehara H., Bloom Et., Okazaki T., et al. : Fractalkine in Vascular Biology : From Basic Research to Clinical Disease. Arterioscler Thromb Vasc Biol 24 : 34–40, 2004.
32. Nanki T., Imai T., Nagasaka K., et al. : Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum 46 : 2878–2883, 2002.
33. Nanki T., Urasaki Y., Imai T., et al. : Inhibition of fractalkine ameliorates murine collagen-induced arthritis. J Immunol 173 : 7010–7016, 2004.
34. Hansson Gk. : Immune Mechanisms in Atherosclerosis. Arterioscler Thromb Vasc Biol 21 : 1876–1890, 2001.
35. Greaves Dr., Hakkinen T., Lucas Ad., et al. : Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 21 : 923–929, 2001.
36. Wong Bwc., Wong D., and Mcmanus Bm. : Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovascular Pathology 11 : 332–338, 2002.
37. Mcdermott Dh., Fong Am., Yang Q., et al. : Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest 111 : 1241–1250, 2003.
38. Mcdermott Dh., Halcox Jp., Schenke Wh., et al. : Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 89 : 401–407, 2001.
39. Lesnik P., Haskell Ca., and Charo If. : Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 111 : 333–340, 2003.
40. Combadiere C., Potteaux S., Gao J. I., et al. : Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107 : 1009–1016, 2003.
41. Greaves Dr. and Channon Km. : Inflammation and immune responses in atherosclerosis. Trends in Immunology 23 : 535–541, 2002.
42. Nakajima T., Schulte S., Warrington Kj., et al. : T-Cell-Mediated Lysis of Endothelial Cells in Acute Coronary Syndromes. Circulation 105 : 570–575, 2002.
43. Zal B., Kaski Jc., Arno G., et al. : Heat-shock protein 60-reactive CD4+CD28null T cells in patients with acute coronary syndromes. Circulation 109 : 1230–1235, 2004.
44. Haskell Ca., Hancock Ww., Salant Dj., et al. : Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest 108 : 679–688, 2001.
45. Robinson La., Nataraj C., Thomas Dw., et al. : A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J Immunol 165 : 6067–6072, 2000.
46. Abdi R., Tran Tb., Sahagun-Ruiz A., et al. : Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 13 : 754–758, 2002.
47. Guo J., Zhang M., Wang B., et al. : Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells. Int J Cancer 103 : 212–220, 2003.
48. Lavergne E., Combadiere B., Bonduelle O., et al. : Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Res 63 : 7468–7474, 2003.
49. Gao Jq., Tsuda Y., Katayama K., et al. : Antitumor Effect by Interleukin-11 Receptor alpha-Locus Chemokine/CCL27, Introduced into Tumor Cells through a Recombinant Adenovirus Vector. Cancer Res 63 : 4420–4425, 2003.
50. Shulby Sa., Dolloff Ng., Stearns Me., et al. : CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 64 : 4693–4698, 2004.
51. Segerer S., Hughes E., Hudkins K. I., et al. : Expression of the fractalkine receptor (CX3CR1) in human kidney diseases. Kidney Int 62 : 488–495, 2002.
52. Feng L., Chen S., Garcia Ge., et al. : Prevention of crescentic glomerulonephritis by im-munoneutralization of the fractalkine receptor CX3CR1 rapid communication. Kidney Int 56 : 612–620, 1999.
53. Foussat A., Bouchet-Delbos L., Berrebi D., et al. : Deregulation of the expression of the fractalkine/fractalkine receptor complex in HIV-1-infected patients. Blood 98 : 1678–1686, 2001.